X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/10/2860737/33485/en/Xenon-Pharmaceuticals-to-Present-at-the-2024-Bloom-Burton-Co-Healthcare-Investor-Conference.html
https://www.globenewswire.com//news-release/2023/12/04/2790471/33485/en/Xenon-Pharmaceuticals-Announces-Closing-of-345-0-Million-Upsized-Public-Offering-Including-Full-Exercise-of-the-Underwriters-Option-to-Purchase-Additional-Shares.html
https://www.globenewswire.com/news-release/2023/12/02/2789643/33485/en/Xenon-Pharmaceuticals-Provides-Updates-on-Neurology-Pipeline-Programs-at-the-Annual-Meeting-of-the-American-Epilepsy-Society-AES-2023.html
https://endpts.com/xenon-offers-300m-in-shares-after-touting-path-ahead-for-mdd-program-despite-phii-miss/
https://www.globenewswire.com//news-release/2023/11/30/2788212/33485/en/Xenon-Pharmaceuticals-Announces-Pricing-of-Upsized-300-0-Million-Public-Offering.html
https://www.globenewswire.com//news-release/2023/11/29/2788081/33485/en/Xenon-Pharmaceuticals-Announces-Proposed-Public-Offering.html
https://www.fiercebiotech.com/biotech/xenon-pharmaceuticals-major-depressive-med-fails-ph-2-eyes-more-fixated-seizure-potential
https://www.globenewswire.com//news-release/2023/11/27/2786024/33485/en/Xenon-Pharmaceuticals-Announces-Topline-Results-from-Phase-2-Proof-of-Concept-X-NOVA-Clinical-Trial-of-XEN1101-in-Major-Depressive-Disorder-MDD.html
https://www.biospace.com/article/neurocrine-hit-with-back-to-back-phase-ii-failures-in-neuropsychiatry/
https://www.fiercebiotech.com/biotech/neurocrine-hit-1-2-punch-takeda-and-xenon-pacts-deliver-midphase-flops
Market Place
Share 
